Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics, Inc. (Nasdaq: VERV) is a cutting-edge biotechnology company headquartered in Cambridge, Massachusetts. With a mission to protect the world from heart disease, Verve is pioneering a transformative approach in cardiovascular care. The company leverages two major breakthroughs in 21st-century biomedicine—human genetics analysis and gene editing—to create life-changing therapies for coronary heart disease.
Verve Therapeutics is focused on developing single-course gene editing medicines to permanently lower LDL cholesterol and triglyceride levels in adults, thereby reducing the risk of coronary heart disease. Their innovative treatments are designed to be administered once in a lifetime, offering a potential shift from chronic disease management to a one-time cure.
Founded by leading experts in cardiovascular medicine, human genetics, and gene editing, Verve has garnered substantial support from top-tier investors, including GV (formerly Google Ventures), Arch Venture Partners, and others. The company was recognized as a '2020 Best Places to Work' by the Boston Business Journal, highlighting its positive workplace culture and innovative environment.
Verve's flagship programs include VERVE-101, VERVE-102, and VERVE-201, each targeting genes validated for their role in lowering low-density lipoprotein cholesterol (LDL-C). Specifically, VERVE-101 and VERVE-102 aim to permanently deactivate the PCSK9 gene, initially targeting patients with heterozygous familial hypercholesterolemia (HeFH) and eventually expanding to treat patients with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C goals using traditional therapies. Meanwhile, VERVE-201 targets the ANGPTL3 gene, focusing on patients with homozygous familial hypercholesterolemia (HoFH) and refractory hypercholesterolemia.
Recent milestones for Verve Therapeutics include the first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. This study demonstrated dose-dependent reductions in disease-causing LDL-C in patients with HeFH. The company is also progressing with the heart-2 phase 1b clinical trial for VERVE-102 and plans to launch a phase 1b trial for VERVE-201 in the latter half of 2024.
In terms of financial performance, Verve maintains a solid cash position, with $624.0 million in cash and marketable securities as of December 31, 2023. This robust financial standing is augmented by strategic partnerships, including a significant collaboration with Eli Lilly, which involved a private placement and potential milestone payments up to $465 million.
Under the leadership of CEO Sekar Kathiresan, M.D., Verve is pushing the boundaries of cardiovascular disease treatment. The company's relentless commitment to scientific excellence and patient care positions it as a potential game-changer in the field of genetic medicine.
Verve Therapeutics reported significant progress toward its clinical initiatives and pipeline advancements in its Q4 and 2021 financial results. The company has substantial cash reserves of $360.4 million, ensuring runway into 2024. They aim to initiate the clinical trial for VERVE-101 targeting heterozygous familial hypercholesterolemia (HeFH) and commence IND-enabling studies for their ANGPTL3 program in the second half of 2022. Despite a net loss of $31.3 million in Q4 2021, Verve's ongoing innovation positions it favorably in addressing cardiovascular diseases.
Verve Therapeutics, a biotechnology firm focused on innovative cardiovascular treatments, will have its CEO, Sekar Kathiresan, present at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 9:10 a.m. ET. The presentation will be available via live webcast on the company’s investor website, archived for 60 days afterward. Verve specializes in gene editing medicines, targeting genes like PCSK9 and ANGPTL3 to lower LDL cholesterol levels, aiming to transform cardiovascular disease care. Their lead candidate, VERVE-101, is in IND-enabling studies, particularly aimed at treating familial hypercholesterolemia.
Verve Therapeutics (VERV) made significant strides in early 2022, announcing key milestones for its cardiovascular gene editing programs. The lead program, VERVE-101, targets the PCSK9 gene to lower LDL-C levels, with regulatory submissions and the first patient treatment expected in the second half of 2022. Preclinical data in non-human primates show promising results, indicating the potential for re-dosing and sequential dosing of therapies. The company is positioned to transition to a clinical-stage organization, aiming for transformative advancements in the treatment of atherosclerotic cardiovascular disease.
Verve Therapeutics, a biotech innovator focused on cardiovascular disease, announced that CEO Sekar Kathiresan will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. The company is pioneering gene editing medicines to transform cardiovascular care, including its lead product candidate VERVE-101, which aims to permanently disable the PCSK9 gene to lower LDL-C levels, particularly for patients with familial hypercholesterolemia. A live webcast will be available on their website and archived for 60 days.
Verve Therapeutics (Nasdaq: VERV) has appointed Allison Dorval as the new Chief Financial Officer. With over 20 years of experience in finance and investor relations from companies like Voyager Therapeutics, her leadership is expected to guide Verve through its next crucial milestones. The firm is advancing its gene editing therapies targeting cardiovascular disease, particularly with the upcoming launch of clinical trials for VERVE-101. This strategic addition comes post-IPO, aimed at bolstering corporate growth and addressing regulatory engagements in 2022.
Verve Therapeutics (Nasdaq: VERV) reported promising preclinical data for its gene editing therapies at TIDES 2021, demonstrating significant PCSK9 protein and LDL-C reductions. The company plans to initiate clinical development of VERVE-101 in 2022, targeting heterozygous familial hypercholesterolemia. Its ANGPTL3 program also showed effective liver-targeted delivery with the proprietary GalNAc-LNP technology. As of September 30, 2021, Verve's cash position stood at $389.2 million, with R&D expenses rising to $17.5 million, reflecting increased investment in future clinical trials.
Verve Therapeutics has announced new preclinical data showcasing its GalNAc-LNP technology for the delivery of an ANGPTL3 base editor in non-human primates (NHPs) with homozygous familial hypercholesterolemia (HoFH). The study demonstrated a 94-97% reduction in blood ANGPTL3 protein levels, along with a nearly 35% decrease in low-density lipoprotein cholesterol (LDL-C). These findings support the potential for broad applicability of this gene editing approach in cardiovascular disease treatments. The company aims to further advance its ANGPTL3 program and initiate investigational new drug-enabling studies in 2022.
Verve Therapeutics announced participation in the Jefferies Gene Therapy/Editing Summit on October 28, 2021, featuring CEO Sekar Kathiresan and CMO Andrew Bellinger. This event will highlight their innovative approach to cardiovascular disease through single-course gene editing medicines. The company's lead candidate, VERVE-101, aims to permanently disable the PCSK9 gene, significantly reducing low-density lipoprotein cholesterol (LDL-C) levels. A live webcast will be accessible on their website, archived for 60 days.
Verve Therapeutics, a biotech firm focused on gene editing for cardiovascular disease, announced participation in the Chardan Virtual 5th Annual Genetics Medicines Conference on October 4, 2021. CEO Sekar Kathiresan and CSO Andrew Bellinger will engage in a fireside chat at 11:00 a.m. ET and a panel discussion at 3:00 p.m. ET. The live webcast will be accessible on the investor section of their website, with an archive available for 60 days. Verve's lead candidate, VERVE-101, targets the PCSK9 gene to lower LDL cholesterol levels, aiming to reduce cardiovascular risk.
Verve Therapeutics has priced its initial public offering (IPO) at $19.00 per share, raising approximately $266.7 million before expenses. The offering consists of 14,035,789 shares, with an additional 2,105,368 shares available to underwriters. This IPO is scheduled to trade on the Nasdaq under the symbol VERV starting June 17, 2021, and is expected to close on June 21, 2021. J.P. Morgan, Jefferies, Guggenheim Securities, and William Blair serve as joint book-running managers for the offering.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
What is Verve Therapeutics' main focus?
Where is Verve Therapeutics headquartered?
What are the key programs of Verve Therapeutics?
Who are some of Verve Therapeutics' investors?
What recent milestone has Verve Therapeutics achieved?
What is the financial condition of Verve Therapeutics?
What is VERVE-101 designed to do?
Who is the CEO of Verve Therapeutics?
What is the significance of Verve's collaboration with Eli Lilly?
What recognition has Verve Therapeutics received?
